SUPPORT FROM

# MANY ANGLES


## Welcome to the Novo Nordisk virtual booth!

[Click here to connect with a Representative]

novo nordisk®

# esperoct®

*antihemophilic factor (recombinant), glycopegylated-exei*



## Move beyond the threshold[a]

Fewer infusions per year compared with standard half-life (SHL) for adults and adolescents

**50%** FEWER INFUSIONS if you previously infused every other day

**40%** FEWER INFUSIONS if you previously infused 3x/week

High factor levels in adults[b] **at or above**

**3%** for **100%** of the time[c]

**5%** for **90%** of the time[d]

**Flexible on the go**

The only EHL product with stability up to **104°F** for up to 3 months

**The largest and longest extended half-life (EHL) clinical trial program**

[a]Of 1% trough factor levels for SHL products in adults and adolescents.
[b]Trough level goal is 1% for prophylaxis.
[c]Data shown are from a study where 175 previously treated adolescents and adults received routine prophylaxis with Esperoct® 50 IU/kg every 4 days. Pre-dose factor activity (trough) levels were evaluated at follow-up visits. Mean trough levels for adolescents (12-<18 years) were 2.7 IU/dL.
[d]Steady-state FVIII activity levels were estimated in 143 adults and adolescents using pharmacokinetic modeling.

EHL = extended half-life

## WHAT IS ESPEROCT®?

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is an injectable medicine to treat and prevent or reduce the number of bleeding episodes in people with hemophilia A. Your healthcare provider may give you Esperoct® when you have surgery

- Esperoct® is not used to treat von Willebrand Disease

## IMPORTANT SAFETY INFORMATION

### Who should not use Esperoct®?

- You should not use Esperoct® if you are allergic to factor VIII or any of the other ingredients of Esperoct® or if you are allergic to hamster proteins

### What is the most important information I need to know about Esperoct®?

- **Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center**
- **Call your healthcare provider right away or get emergency treatment right away if you get any signs of an allergic reaction, such as:** hives, chest tightness, wheezing, dizziness, difficulty breathing, and/or swelling of the face

### What should I tell my healthcare provider before using Esperoct®?

- Before taking Esperoct®, you should tell your healthcare provider if you have or have had any medical conditions, take any medicines (including non-prescription medicines and dietary supplements), are nursing, pregnant or planning to become pregnant, or have been told that you have inhibitors to factor VIII
- Your body can make antibodies called "inhibitors" against Esperoct®, which may stop Esperoct® from working properly. **Call your healthcare provider right away if your bleeding does not stop after taking Esperoct®**

### What are the possible side effects of Esperoct®?

- Common side effects of Esperoct® include rash or itching, and swelling, pain, rash or redness at the location of infusion

**Please see a Novo Nordisk Representative for Prescribing Information.**

Esperoct® is a prescription medication. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

**Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536 U.S.A.**

 Printed in the U.S.A. US20ESP00032 April 2020

novo nordisk®

**NovoSeven® RT**
*Coagulation Factor VIIa (Recombinant)*

# NovoSeven® RT: Experience where it matters

***Miguel** lives with hemophilia B with inhibitors and uses NovoSeven® RT.*

STILL RECOMBINANT AND RAPID TO USE
AFTER 30 YEARS[a]
STILL CONTROLLING BLEEDS

## SAFETY

**Low rate (0.2%) of blood clots[b] and recombinant technology and manufacturing**

[b]In patients with congenital hemophilia A or B with inhibitors.

## BLEED CONTROL

**Proven bleed control**

## SPEED

**Fast to mix and fast to infuse[c]**

[c]Administer as a slow bolus injection over 2-5 minutes.

[a]Compassionate use, also known as expanded access, began enrolling in 1988; FDA approval received in 1999.

## What is NovoSeven® RT?

NovoSeven® RT (coagulation Factor VIIa, recombinant) is an injectable medicine used for:

- Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann's thrombasthenia with a decreased or absent response to platelet transfusions
- Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia

## Important Safety Information

### What is the most important information I should know about NovoSeven® RT?

**NovoSeven® RT may cause serious side effects, including:**

- **Serious blood clots** that form in veins and arteries with the use of NovoSeven® RT have been reported
- Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function
- Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT
- You should not use NovoSeven® RT if you have ever had allergic (hypersensitivity) reactions, including severe, whole body reactions (anaphylaxis) to NovoSeven® RT, any of its ingredients, or mice, hamsters, or cows. Signs of allergic reaction include shortness of breath, rash, itching (pruritus), redness of the skin (erythema), or fainting/dizziness

### What should I tell my healthcare provider before using NovoSeven® RT?

- Tell your healthcare provider if you have any of the following, as these may increase your risk of blood clots:
  - congenital hemophilia and are also receiving treatment with aPCCs (activated prothrombin complex concentrates)
  - are an older patient particularly with acquired hemophilia and receiving other agents to stop bleeding
  - history of heart or blood vessel diseases
- Tell your healthcare provider and pharmacist about all the medicines you take, including all prescription and non-prescription medicines, such as over-the-counter medicines, supplements, or herbal remedies

### What are the possible side effects of NovoSeven® RT?

- The most common and serious side effects are blood clots
- Tell your healthcare provider about any side effects that bother you or do not go away, and seek medical help right away if you have signs of a blood clot or allergic reaction

**Please see a Novo Nordisk Representative for Prescribing Information.**

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. NovoSeven® RT is a prescription medication. Novo Nordisk provides patient assistance for those who qualify. Please call **1-877-NOVO-777** (1-877-668-6777) to learn more about Novo Nordisk assistance programs.

**Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536 U.S.A.**

 Printed in the U.S.A. US20NSVN00029 April 2020

novo nordisk®

rebinyn®

*Coagulation Factor IX (Recombinant), GlycoPEGylated*

In hemophilia B,

# TAKE CONTROL TO A HIGH LEVEL WITH REBINYN®

Abdiel, 25 years old, has hemophilia B and uses Rebinyn®.

Rebinyn® elevates factor above your normal levels[a]

**+94%** Factor IX levels achieved after an infusion[b]

**17%** FIX levels sustained after 7 days[a]

With a single dose of Rebinyn® 40 IU/kg in adults with ≤2% FIX levels[a]

Rebinyn® achieved an **83-hr** average half-life in adults[a]

Achieve higher factor levels for longer

Rebinyn® provides **5X** longer half-life than BeneFIX®[c]

[a]In two phase 3 studies, factor levels were evaluated for 1 week after the first dose of Rebinyn® 40 IU/kg. The average levels after 7 days were 16.8% in 6 adults, 14.6% in 3 adolescents, 10.9% in 13 children ages 7-12 years, and 8.4% in 12 children up to age 6 years.
[b]Based upon a 2.34% increase in factor levels per IU/kg infused in adults.
[c]Based upon a phase 1 study comparing 25, 50, and 100 IU/kg doses of Rebinyn® to a 50 IU/kg dose of standard half-life rFIX in 7 adults and a 50 IU/kg dose of plasma-derived FIX in 8 adults. For Rebinyn®, estimated average FIX activity is adjusted to a dose of 50 IU/kg.
[d]In a single-dose study compared with SHL FIX.

## INDICATIONS AND USAGE

### What is Rebinyn® Coagulation Factor IX (Recombinant), GlycoPEGylated?

Rebinyn® is an injectable medicine used to replace clotting Factor IX that is missing in patients with hemophilia B. Rebinyn® is used to treat and control bleeding in people with hemophilia B. Your healthcare provider may give you Rebinyn® when you have surgery. Rebinyn® is not used for routine prophylaxis or for immune tolerance therapy.

## IMPORTANT SAFETY INFORMATION

### What is the most important information I need to know about Rebinyn®?

- **Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center.** Carefully follow your healthcare provider's instructions regarding the dose and schedule for infusing Rebinyn®.

### Who should not use Rebinyn®?

Do not use Rebinyn® if you:

- are allergic to Factor IX or any of the other ingredients of Rebinyn®.
- are allergic to hamster proteins.

### What should I tell my health care provider before using Rebinyn®?

Tell your health care provider if you:

- have or have had any medical conditions.
- take any medicines, including non-prescription medicines and dietary supplements.
- are nursing, pregnant, or plan to become pregnant.
- have been told you have inhibitors to Factor IX.

In this study, estimated Rebinyn® factor levels stayed above **1%** for **22.5 days**.[c]

- Rebinyn® is not used for routine prophylaxis or for immune tolerance therapy
- Animals given repeat doses of Rebinyn® showed Polyethylene Glycol (PEG) inside cells lining blood vessels in the choroid plexus, which makes the fluid that cushions the brain. The potential human implications of these animal tests are unknown.

### How should I use Rebinyn®?

- Rebinyn® is given as an infusion into the vein.
- **Call your healthcare provider right away if your bleeding does not stop after taking Rebinyn®.**
- Do not stop using Rebinyn® without consulting your healthcare provider.

### What are the possible side effects of Rebinyn®?

- **Common side effects include** swelling, pain, rash or redness at the location of the infusion, and itching.
- **Call your healthcare provider right away or get emergency treatment right away if you get any of the following signs of an allergic reaction:** hives, chest tightness, wheezing, difficulty breathing, and/or swelling of the face.
- **Tell your healthcare provider about any side effect that bothers you or that does not go away.**
- Animals given repeat doses of Rebinyn® showed Polyethylene Glycol (PEG) inside cells lining blood vessels in the choroid plexus, which makes the fluid that cushions the brain. The potential human implications of these animal tests are unknown.

**Please see a Novo Nordisk Representative for Prescribing Information.**

Rebinyn® is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

**Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536 U.S.A.**



novo nordisk®

**tretten®**
*Coagulation Factor XIII A-Subunit (Recombinant)*




**The only recombinant therapy for congenital factor XIII A-subunit deficiency**

**Proven efficacy and safety in clinical trials**

ABR=annual bleed rate.

**Convenient once-monthly, low-volume prophylaxis[a]**

[a]In patients with congenital FXIII A-subunit deficiency.

## Indications and Usage

### What is Tretten® (Coagulation Factor XIII A-Subunit [Recombinant])?

- Tretten® is an injectable medicine used to prevent bleeding in adults and children who have congenital Factor XIII (FXIII) A-subunit deficiency.
- Tretten® is not for use in patients with congenital Factor XIII B-subunit deficiency.

## Important Safety Information

### Who should not use Tretten®?

- You should not use Tretten® if you have ever had allergic (hypersensitivity) reactions, including severe, whole body reaction (anaphylaxis) to Tretten® or any of the ingredients.

### What should I tell my healthcare provider before Tretten® is given?

- Tell your healthcare provider about all of your medical conditions, including if you are pregnant, think you may be pregnant or planning to become pregnant, are breast feeding, or have a history of blood clots.
- Tell your healthcare provider and pharmacist about all of the medicines you take, including all prescription and non-prescription medicines such as over-the-counter medicines, supplements, or herbal remedies.

## Important Safety Information *(cont'd)*

### What are the possible side effects of Tretten®?

- Call your healthcare provider or go to the emergency department right away if you have any of the following symptoms after using Tretten®:
  - Signs of allergic reaction, including shortness of breath, rash, itching (pruritus), redness of the skin (erythema), or fainting/dizziness.
  - Signs of a blood clot including pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, or sudden severe headache and/or loss of consciousness or function.
  - Unexpected bleeding.
- Other possible side effects may include pain in your arms or legs, headache, and pain at the injection site.
- These are not all the possible side effects of Tretten®. Tell your healthcare provider about any side effect that bothers you or that does not go away.

**Please see a Novo Nordisk Representative at the booth for Prescribing Information.**

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Tretten® is a prescription medication. Novo Nordisk provides patient assistance for those who qualify. Please call **1-844-Tretten** (1-844-873-8836) to learn more about Novo Nordisk assistance programs.

**Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536 U.S.A.**



novo nordisk®